Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS Pharmaceutical Accounts Payable & Accrued Expense Historical Data
* Premium members only.
The historical data trend for COSMOS Pharmaceutical's Accounts Payable & Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.
Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.
It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.
What does a Accounts Payable & Accrued Expense of $1,368 Mil mean?
COSMOS Pharmaceutical (CSMYF) has a Accounts Payable & Accrued Expense of $1,368 Mil as of May. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on COSMOS Pharmaceutical and its competitors.
Is COSMOS Pharmaceutical's Accounts Payable & Accrued Expense too high?
COSMOS Pharmaceutical's current Accounts Payable & Accrued Expense is $1,368 Mil. Overall, COSMOS Pharmaceutical has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's Accounts Payable & Accrued Expense compare to competitors?
COSMOS Pharmaceutical's Accounts Payable & Accrued Expense of $1,368 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Healthcare Providers & Services company?
A good Accounts Payable & Accrued Expense depends on the Healthcare Providers & Services industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on COSMOS Pharmaceutical and its competitors. COSMOS Pharmaceutical's current Accounts Payable & Accrued Expense is $1,368 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
COSMOS Pharmaceutical (CSMYF) has a current Accounts Payable & Accrued Expense of $1,368 Mil. The stock's GF Value™ is $48.51, compared to a current price of $37.06 — trading 23.6% below its estimated fair value. The current Accounts Payable & Accrued Expense is $1,368 Mil. COSMOS Pharmaceutical's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current Accounts Payable & Accrued Expense is $1,368 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 23.6% below its estimated GF Value™ of $48.51.
Key valuation signals for CSMYF:
Accounts Payable & Accrued Expense: $1,368 Mil
GF Value™: $48.51 vs. price of $37.06 (23.6% below fair value)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
89GF Score
Get the complete analysis for CSMYF
Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
